GCEIP 500 Company profile
Sun Pharmaceutical Industries Limited
Sun Pharma sells medicines in more than 100 countries. In FY2024–25, specialty medicines generated US$1.216 billion in revenue, while the company also reported manufacturing-compliance challenges in the United States.
The company
What it does
Sun Pharma is an Indian multinational pharmaceutical company that develops and manufactures branded, generic and specialty medicines for domestic and international markets.
Across markets
The FY2024–25 annual report describes sales across the United States, India, emerging markets and the rest of the world, with products distributed in more than 100 countries. India accounted for about one-third of revenue, while the United States accounted for about 31%. These figures show geographic reach, not the number of patients treated or medicines made affordable. The company also disclosed US manufacturing compliance issues affecting its generics business, a material quality and supply risk.
The company’s footprint and context are linked to the public sources below.
GCEIP view
What the record tells us
Sun Pharma’s international reach rests on branded generics and specialty medicines. Company scale does not establish therapeutic benefit or patient access; those questions need evidence on regulatory quality, affordability and patient outcomes. Its 2025 WCRC rank is a size indicator only.
Published recognition
Selected results
See published awards and company-list results 1 sources
- WCRC 1000 · 2026View source
Market-capitalisation order
Ranked #17 in the 2026 WCRC 1000; candidate discovery only, no award points.